newsfilter
← Latest News
PR Newswire·

OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein

OncoSec Medical Incorporated (NASDAQ: ONCS) today announced that it has dosed several subjects in its Phase 1 clinical trial of CORVax12, the only...